Ads
related to: experimental lung cancer drugs- Learn About Treatment
Discover Why This aNSCLC Treatment
Option May Be Right For You.
- aNSCLC Treatment Option
Visit The Patient Website Today To
Learn About This Treatment Option.
- aNSCLC Patient Support
Find Helpful Resources & Get
Answers About A Treatment Option.
- How This Treatment Works
Explore Important Treatment Info
On The Official Patient Website.
- Learn About Treatment
consumerhippo.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell ...
Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients ...
Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday.
Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). [1] [2] It has been granted Orphan drug status for Merkel cell carcinoma. [3] It has reported encouraging Phase II results for small-cell lung cancer. [4]
Patritumab deruxtecan (U3-1402/ MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer. [ 1 ] [ 2 ] [ 3 ] References
Merck's experimental anti-TIGIT drug vibostolimab in combination with its approved therapy Keytruda also failed to improve overall survival in a study of patients with non-small-cell lung cancer ...
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. [1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. [2] It has been given conditional approval for these indication in China. [3]
Ads
related to: experimental lung cancer drugsconsumerhippo.com has been visited by 100K+ users in the past month